NYSEAMERICAN:MTNB

Matinas BioPharma Competitors

$1.01
-0.01 (-0.98 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.00
Now: $1.01
$1.04
50-Day Range
$0.88
MA: $1.11
$1.74
52-Week Range
$0.60
Now: $1.01
$2.22
Volume1.09 million shs
Average Volume4.80 million shs
Market Capitalization$206.32 million
P/E RatioN/A
Dividend YieldN/A
Beta3

Competitors

Matinas BioPharma (NYSEAMERICAN:MTNB) Vs. CXRXF, COLL, ORIC, LXRX, ESPR, and KPTI

Should you be buying MTNB stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Matinas BioPharma, including ADVANZ PHARMA (CXRXF), Collegium Pharmaceutical (COLL), ORIC Pharmaceuticals (ORIC), Lexicon Pharmaceuticals (LXRX), Esperion Therapeutics (ESPR), and Karyopharm Therapeutics (KPTI).

ADVANZ PHARMA (OTCMKTS:CXRXF) and Matinas BioPharma (NYSEAMERICAN:MTNB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations.

Institutional and Insider Ownership

22.8% of Matinas BioPharma shares are owned by institutional investors. 7.8% of Matinas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for ADVANZ PHARMA and Matinas BioPharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ADVANZ PHARMA0000N/A
Matinas BioPharma00403.00

Matinas BioPharma has a consensus price target of $3.3750, indicating a potential upside of 234.16%. Given Matinas BioPharma's higher possible upside, analysts clearly believe Matinas BioPharma is more favorable than ADVANZ PHARMA.

Profitability

This table compares ADVANZ PHARMA and Matinas BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ADVANZ PHARMA-19.88%N/A-3.08%
Matinas BioPharmaN/A-37.07%-31.41%

Earnings and Valuation

This table compares ADVANZ PHARMA and Matinas BioPharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADVANZ PHARMA$508.32 million1.62$-196,020,000.00N/AN/A
Matinas BioPharma$90,000.002,292.43$-17,370,000.00($0.13)-7.77

Matinas BioPharma has lower revenue, but higher earnings than ADVANZ PHARMA.

Summary

Matinas BioPharma beats ADVANZ PHARMA on 8 of the 11 factors compared between the two stocks.

Collegium Pharmaceutical (NASDAQ:COLL) and Matinas BioPharma (NYSEAMERICAN:MTNB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Collegium Pharmaceutical and Matinas BioPharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Collegium Pharmaceutical11202.25
Matinas BioPharma00403.00

Collegium Pharmaceutical presently has a consensus price target of $25.00, indicating a potential upside of 7.16%. Matinas BioPharma has a consensus price target of $3.3750, indicating a potential upside of 234.16%. Given Matinas BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Matinas BioPharma is more favorable than Collegium Pharmaceutical.

Institutional & Insider Ownership

22.8% of Matinas BioPharma shares are owned by institutional investors. 8.1% of Collegium Pharmaceutical shares are owned by company insiders. Comparatively, 7.8% of Matinas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Collegium Pharmaceutical has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, Matinas BioPharma has a beta of 3, suggesting that its share price is 200% more volatile than the S&P 500.

Profitability

This table compares Collegium Pharmaceutical and Matinas BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Collegium Pharmaceutical5.71%12.64%3.15%
Matinas BioPharmaN/A-37.07%-31.41%

Valuation and Earnings

This table compares Collegium Pharmaceutical and Matinas BioPharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Collegium Pharmaceutical$296.70 million2.73$-22,720,000.00($0.68)-34.31
Matinas BioPharma$90,000.002,292.43$-17,370,000.00($0.13)-7.77

Matinas BioPharma has lower revenue, but higher earnings than Collegium Pharmaceutical. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than Matinas BioPharma, indicating that it is currently the more affordable of the two stocks.

Summary

Matinas BioPharma beats Collegium Pharmaceutical on 8 of the 14 factors compared between the two stocks.

ORIC Pharmaceuticals (NASDAQ:ORIC) and Matinas BioPharma (NYSEAMERICAN:MTNB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for ORIC Pharmaceuticals and Matinas BioPharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ORIC Pharmaceuticals01602.86
Matinas BioPharma00403.00

ORIC Pharmaceuticals presently has a consensus price target of $43.7143, indicating a potential upside of 102.66%. Matinas BioPharma has a consensus price target of $3.3750, indicating a potential upside of 234.16%. Given Matinas BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Matinas BioPharma is more favorable than ORIC Pharmaceuticals.

Institutional & Insider Ownership

73.4% of ORIC Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.8% of Matinas BioPharma shares are owned by institutional investors. 7.8% of Matinas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares ORIC Pharmaceuticals and Matinas BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ORIC PharmaceuticalsN/AN/AN/A
Matinas BioPharmaN/A-37.07%-31.41%

Valuation and Earnings

This table compares ORIC Pharmaceuticals and Matinas BioPharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ORIC PharmaceuticalsN/AN/AN/AN/AN/A
Matinas BioPharma$90,000.002,292.43$-17,370,000.00($0.13)-7.77

ORIC Pharmaceuticals has higher earnings, but lower revenue than Matinas BioPharma.

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Matinas BioPharma (NYSEAMERICAN:MTNB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Lexicon Pharmaceuticals and Matinas BioPharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lexicon Pharmaceuticals06202.25
Matinas BioPharma00403.00

Lexicon Pharmaceuticals presently has a consensus price target of $9.40, indicating a potential upside of 75.05%. Matinas BioPharma has a consensus price target of $3.3750, indicating a potential upside of 234.16%. Given Matinas BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Matinas BioPharma is more favorable than Lexicon Pharmaceuticals.

Institutional & Insider Ownership

84.6% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.8% of Matinas BioPharma shares are owned by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are owned by company insiders. Comparatively, 7.8% of Matinas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Lexicon Pharmaceuticals has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500. Comparatively, Matinas BioPharma has a beta of 3, suggesting that its share price is 200% more volatile than the S&P 500.

Profitability

This table compares Lexicon Pharmaceuticals and Matinas BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lexicon Pharmaceuticals-320.44%-164.96%-31.83%
Matinas BioPharmaN/A-37.07%-31.41%

Valuation and Earnings

This table compares Lexicon Pharmaceuticals and Matinas BioPharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexicon Pharmaceuticals$322.07 million2.41$130.13 million$1.353.98
Matinas BioPharma$90,000.002,292.43$-17,370,000.00($0.13)-7.77

Lexicon Pharmaceuticals has higher revenue and earnings than Matinas BioPharma. Matinas BioPharma is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Matinas BioPharma beats Lexicon Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Esperion Therapeutics (NASDAQ:ESPR) and Matinas BioPharma (NYSEAMERICAN:MTNB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Esperion Therapeutics and Matinas BioPharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Esperion Therapeutics24312.30
Matinas BioPharma00403.00

Esperion Therapeutics presently has a consensus price target of $50.60, indicating a potential upside of 87.76%. Matinas BioPharma has a consensus price target of $3.3750, indicating a potential upside of 234.16%. Given Matinas BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Matinas BioPharma is more favorable than Esperion Therapeutics.

Valuation and Earnings

This table compares Esperion Therapeutics and Matinas BioPharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Esperion Therapeutics$148.36 million5.08$-97,170,000.00($3.59)-7.51
Matinas BioPharma$90,000.002,292.43$-17,370,000.00($0.13)-7.77

Matinas BioPharma has lower revenue, but higher earnings than Esperion Therapeutics. Matinas BioPharma is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Esperion Therapeutics and Matinas BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Esperion Therapeutics-46.15%-629.88%-41.43%
Matinas BioPharmaN/A-37.07%-31.41%

Institutional & Insider Ownership

22.8% of Matinas BioPharma shares are owned by institutional investors. 7.7% of Esperion Therapeutics shares are owned by company insiders. Comparatively, 7.8% of Matinas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Esperion Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, Matinas BioPharma has a beta of 3, suggesting that its share price is 200% more volatile than the S&P 500.

Summary

Matinas BioPharma beats Esperion Therapeutics on 12 of the 15 factors compared between the two stocks.

Matinas BioPharma (NYSEAMERICAN:MTNB) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Matinas BioPharma and Karyopharm Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Matinas BioPharma00403.00
Karyopharm Therapeutics01802.89

Matinas BioPharma currently has a consensus target price of $3.3750, indicating a potential upside of 234.16%. Karyopharm Therapeutics has a consensus target price of $30.6250, indicating a potential upside of 205.64%. Given Matinas BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Matinas BioPharma is more favorable than Karyopharm Therapeutics.

Valuation & Earnings

This table compares Matinas BioPharma and Karyopharm Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Matinas BioPharma$90,000.002,292.43$-17,370,000.00($0.13)-7.77
Karyopharm Therapeutics$40.89 million18.29$-199,590,000.00($3.22)-3.11

Matinas BioPharma has higher earnings, but lower revenue than Karyopharm Therapeutics. Matinas BioPharma is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Matinas BioPharma and Karyopharm Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Matinas BioPharmaN/A-37.07%-31.41%
Karyopharm Therapeutics-221.23%-187.66%-56.42%

Institutional and Insider Ownership

22.8% of Matinas BioPharma shares are held by institutional investors. Comparatively, 88.6% of Karyopharm Therapeutics shares are held by institutional investors. 7.8% of Matinas BioPharma shares are held by insiders. Comparatively, 13.3% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Matinas BioPharma has a beta of 3, suggesting that its share price is 200% more volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.

Summary

Matinas BioPharma beats Karyopharm Therapeutics on 9 of the 14 factors compared between the two stocks.


Matinas BioPharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ADVANZ PHARMA logo
CXRXF
ADVANZ PHARMA
0.5$16.80-0.9%$821.74 million$508.32 million-8.04
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.33-1.3%$810.86 million$296.70 million47.61
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.57-7.5%$791.51 millionN/A0.00Gap Down
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.37-1.1%$775.18 million$322.07 million-5.11
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$26.95-4.7%$753.06 million$148.36 million-7.00News Coverage
Gap Down
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$10.02-1.2%$747.83 million$40.89 million-3.46
Veru logo
VERU
Veru
1.4$10.35-0.3%$744.29 million$42.59 million-36.96
Ardelyx logo
ARDX
Ardelyx
1.6$7.44-5.6%$734.18 million$5.28 million-7.37Gap Down
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$22.17-5.3%$731.97 million$252 million-2.27Gap Down
Chimerix logo
CMRX
Chimerix
1.3$8.45-2.1%$723.99 million$12.52 million-14.82News Coverage
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.82-1.8%$716.29 million$2.22 million-16.59
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.32-2.1%$714.48 million$150,000.00-4.74Gap Down
OrganiGram logo
OGI
OrganiGram
1.6$3.05-3.3%$708.43 million$64.61 million-4.49Upcoming Earnings
Analyst Upgrade
Gap Down
BLUSF
BELLUS Health
0.5$4.38-2.1%$696.93 million$30,000.000.00Gap Up
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$27.50-0.0%$686.58 million$19.56 million-19.78High Trading Volume
EMIS
Emisphere Technologies
0.9$7.81-0.0%$673.08 millionN/A0.00
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.74-3.3%$660.12 millionN/A-2.46Gap Down
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$28.38-13.7%$655.29 million$13.80 million-13.71Insider Selling
High Trading Volume
News Coverage
Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.23-5.6%$651.22 million$143.01 million-1.19Gap Down
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$19.86-9.5%$640.68 millionN/A-10.56Gap Down
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$26.15-0.1%$635.65 million$12.69 million-12.57
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$17.62-1.3%$630.96 million$6.83 million-18.16News Coverage
Kadmon logo
KDMN
Kadmon
1.8$3.66-5.2%$628.85 million$5.09 million-6.10Analyst Upgrade
Gap Down
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$32.88-2.4%$628.47 million$9.64 million-5.36
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$14.82-3.0%$624.78 million$17.26 million-4.12Earnings Announcement
Analyst Revision
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$12.32-9.9%$598.21 millionN/A-6.32Analyst Upgrade
News Coverage
Gap Down
Evolus logo
EOLS
Evolus
1.1$13.58-2.4%$593.89 million$34.92 million-6.69Analyst Report
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$35.23-2.0%$590.00 millionN/A-16.31Gap Down
AnaptysBio logo
ANAB
AnaptysBio
1.5$20.87-6.3%$571.13 million$8 million-7.70Gap Down
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$12.04-4.1%$568.85 millionN/A-9.33Gap Down
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$15.52-3.3%$567.69 millionN/A-4.47News Coverage
Gap Up
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$17.07-4.9%$563.81 million$1.19 million-7.11Insider Buying
News Coverage
Gap Down
Inventiva logo
IVA
Inventiva
0.0$14.44-2.2%$557.76 millionN/A0.00Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.26-1.8%$554.59 million$59.29 million-21.73
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.20-5.2%$553.64 millionN/A-5.29Analyst Upgrade
Gap Down
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.4$41.56-0.9%$549.30 million$195.89 million118.75News Coverage
SIGA
SIGA Technologies
0.3$7.10-0.6%$544.91 million$26.74 million17.75
Basilea Pharmaceutica logo
BPMUF
Basilea Pharmaceutica
0.6$50.20-0.0%$539.18 million$135.28 million-24.02Analyst Upgrade
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$39.66-5.1%$535.77 million$40,000.00-1.72High Trading Volume
Gap Up
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$10.04-0.2%$535.48 millionN/A-4.03
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24-0.0%$531.75 millionN/A-3.15
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.32-0.0%$530.72 million$49.65 million-1.86News Coverage
Gap Down
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.87-4.3%$529.13 millionN/A-4.66Gap Down
89bio logo
ETNB
89bio
1.6$26.28-0.2%$524.18 millionN/A-5.20
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$21.04-5.1%$523.18 millionN/A-8.28News Coverage
Gap Down
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$5.44-10.3%$516.29 million$36.63 million-6.40Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Gap Up
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.78-0.0%$513.32 million$59.22 million43.90News Coverage
Provention Bio logo
PRVB
Provention Bio
1.6$8.00-21.6%$507 millionN/A-5.37Analyst Report
High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$11.97-0.9%$506.64 million$25 million-18.42
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$14.00-0.3%$502.28 million$58.12 million-16.28
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.